Challenging Adverse Events with GPRC5D-Targeted Therapies

Opinion
Video

Panelists discuss how cytokine release syndrome and neurological toxicities have been the most challenging adverse events to manage with GPRC5D-targeted therapies, requiring proactive monitoring and intervention strategies, while noting that these side effects are generally similar to those seen with other bispecifics.

  • What adverse events have been most challenging to manage with GPRC5D-targeted therapies?
  • How are these being managed?
  • Do the AEs differ from other bispecifics?
  • In what ways could the availability of GPRC5D-targeted therapies impact the broader therapeutic landscape for RRMM in community practices?
Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content